Novartis, Amgen, and Eli Lilly are advancing into the late-stage trials of innovative therapies targeting lipoprotein(a) or Lp(a), a cholesterol variant linked to heightened heart attack risks. With approximately 20% of the global population affected by elevated Lp(a) levels and limited treatment options available, these companies are poised to potentially transform cardiology if their drugs prove effective. Novartis is set to release critical trial results for its drug pelacarsen later this year, which could set the tone for the entire Lp(a) drug pipeline.

The implications for the pharmaceutical market are significant. If successful, these therapies could generate annual sales of up to $5.6 billion by 2032, as estimated by Evaluate. However, investor sentiment remains cautious due to uncertainties surrounding trial outcomes and the timeline for market entry. The success of Novartis’ trial could catalyze interest in Lp(a) screening and treatment, similar to the trajectory seen with PCSK9 inhibitors.

As the landscape evolves, market professionals should monitor the upcoming trial results closely. The outcomes could not only validate the Lp(a) hypothesis but also reshape treatment paradigms, potentially unlocking a new segment in the cardiovascular therapeutics market.

Source: cnbc.com